Form 4: ARS Pharmaceuticals Chief Medical Officer Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold a portion of her shares through a pre-arranged 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock on November 12, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
• The transactions involved the sale of shares held directly and indirectly through various trusts.
• A total of 45,045 shares were sold at a weighted average price of $16.7589, with prices ranging from $16.405 to $17.395.
• An additional 4,955 shares were sold at a weighted average price of $17.643, with prices ranging from $17.42 to $17.85.
• Another 45,124 shares were sold at a weighted average price of $16.7604, with prices ranging from $16.40 to $17.39.
• Finally, 4,876 shares were sold at a weighted average price of $17.6416, with prices ranging from $17.42 to $17.83.
• The sales were made from shares held directly and through trusts including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust.
• Following these transactions, Ms. Tanimoto still holds a significant number of shares both directly and indirectly.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Risks

• Sales by insiders, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.
• The volume of shares sold could potentially exert downward pressure on the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of illegal insider trading. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector such as Amgen (AMGN) and Gilead Sciences (GILD).
• These plans allow insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.
• The reported sales are within the typical range of insider transactions and do not appear to be unusual compared to similar filings from other companies.

Stakeholder Impact

• The sales may have a minor impact on the stock price, but the pre-arranged nature of the transactions should mitigate any significant negative reaction.
• Shareholders may view the sales as a routine part of executive compensation and financial planning.

Key Dates

Keywords

insider trading, Form 4, 10b5-1 plan, stock sale, ARS Pharmaceuticals, Sarina Tanimoto, SPRY, share transaction